Compare SPCE & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | CDXS |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.5M | 141.8M |
| IPO Year | 2017 | 2008 |
| Metric | SPCE | CDXS |
|---|---|---|
| Price | $3.05 | $2.15 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.26 | N/A |
| AVG Volume (30 Days) | ★ 5.6M | 3.2M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.84 | 43.82 |
| EPS | N/A | ★ N/A |
| Revenue | $1,544,000.00 | ★ $138,590,000.00 |
| Revenue This Year | $2,766.13 | $6.35 |
| Revenue Next Year | $699.18 | $16.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $2.13 | $0.96 |
| 52 Week High | $5.59 | $3.87 |
| Indicator | SPCE | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 67.41 | 73.88 |
| Support Level | $2.91 | $1.57 |
| Resistance Level | $3.42 | $2.56 |
| Average True Range (ATR) | 0.23 | 0.15 |
| MACD | 0.08 | 0.05 |
| Stochastic Oscillator | 77.31 | 96.33 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.